Intelligence Driven Advisers LLC acquired a new position in shares of Stryker Co. (NYSE:SYK – Free Report) in the 3rd quarter, HoldingsChannel reports. The fund acquired 681 shares of the medical technology company’s stock, valued at approximately $246,000.
Several other large investors also recently modified their holdings of SYK. Centennial Bank AR boosted its stake in Stryker by 106.7% during the second quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock worth $32,000 after acquiring an additional 48 shares in the last quarter. HBW Advisory Services LLC acquired a new stake in shares of Stryker in the 3rd quarter valued at about $42,000. Hara Capital LLC bought a new stake in Stryker in the 3rd quarter valued at about $42,000. Grove Bank & Trust increased its position in Stryker by 84.8% in the 3rd quarter. Grove Bank & Trust now owns 122 shares of the medical technology company’s stock valued at $44,000 after buying an additional 56 shares in the last quarter. Finally, DT Investment Partners LLC boosted its holdings in Stryker by 114.3% in the third quarter. DT Investment Partners LLC now owns 135 shares of the medical technology company’s stock worth $49,000 after acquiring an additional 72 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.
Insider Buying and Selling at Stryker
In other news, insider Viju Menon sold 600 shares of Stryker stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total value of $213,000.00. Following the completion of the transaction, the insider now directly owns 9,069 shares in the company, valued at approximately $3,219,495. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the transaction, the chief executive officer now directly owns 100,027 shares in the company, valued at $36,879,954.90. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Viju Menon sold 600 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total value of $213,000.00. Following the completion of the sale, the insider now owns 9,069 shares in the company, valued at $3,219,495. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 67,381 shares of company stock valued at $24,825,275 in the last 90 days. 5.90% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
Stryker Stock Performance
Shares of SYK stock traded up $2.52 on Thursday, hitting $390.86. 58,114 shares of the stock were exchanged, compared to its average volume of 1,251,477. The firm’s 50 day moving average is $362.94 and its two-hundred day moving average is $346.72. Stryker Co. has a one year low of $282.35 and a one year high of $392.11. The firm has a market capitalization of $149.00 billion, a PE ratio of 41.62, a P/E/G ratio of 2.92 and a beta of 0.91. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66.
Stryker (NYSE:SYK – Get Free Report) last issued its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The firm had revenue of $5.49 billion during the quarter, compared to analyst estimates of $5.37 billion. During the same quarter last year, the business earned $2.46 earnings per share. The company’s quarterly revenue was up 11.9% on a year-over-year basis. Sell-side analysts expect that Stryker Co. will post 12.06 earnings per share for the current fiscal year.
About Stryker
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
See Also
- Five stocks we like better than Stryker
- Buy P&G Now, Before It Sets A New All-Time High
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Occidental Petroleum Hits New Low: Will Buffett Take the Bait?
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Top 3 R&D-Driven Stocks Showing Strong Profit and Momentum
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK – Free Report).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.